SHARE PRICE INFORMATION

Corporate Presentations

View All >>

ASX ANNOUNCEMENTS

Date Price Sensitive Headline
27-Nov-20 Replacement Constitution
27-Nov-20 Results of Annual General Meeting
27-Nov-20 AGM Presentations
17-Nov-20 Appendix 3Y x 4
17-Nov-20 Appendix 2A
13-Nov-20 $ Completion of Entitlement Offer
09-Nov-20 $ Actinogen files new patent applications
05-Nov-20 Retail Entitlement Offer-Closing Date Reminder
04-Nov-20 $ FDA IND Update
02-Nov-20 $ ACW to initiate XanaFX clinical trial in Fragile X syndrome
30-Oct-20 Update to Appendix 3B
29-Oct-20 $ Quarterly Activity Report & Appendix 4C
27-Oct-20 $ R&D Tax Incentive Rebate received of A$2.9 million
26-Oct-20 Annual Report to Shareholders
26-Oct-20 Letter to Shareholders, Notice of AGM & Proxy Form
26-Oct-20 Incorrect BPAY Biller Code provided by share registry
26-Oct-20 Change in substantial holding
23-Oct-20 Correction of Entitlement Offer allotment date
23-Oct-20 Letter to Ineligible Shareholders
23-Oct-20 $ Offer Booklet
22-Oct-20 Cleansing Notice
22-Oct-20 Appendix 2A
16-Oct-20 Change to Date of Annual General Meeting
15-Oct-20 Letter to Optionholders re Non-Renounceable Rights Issue
15-Oct-20 $ Actinogen Presentation & Planned Conference Call
15-Oct-20 Notice under Section 708AA of the Corporations Act 2001 (Cth)
15-Oct-20 $ Proposed issue of Securities – ACW
15-Oct-20 $ ACW announces two clinical trials & launches capital raising
13-Oct-20 $ Trading Halt
02-Oct-20 Appendix 3G
29-Sep-20 Date of AGM & Closing Date for Director Nominations
28-Sep-20 Actinogen Appoints Chief Financial Officer
09-Sep-20 Actinogen Medical Investor Presentation
26-Aug-20 $ Appendix 4E & Annual Report
26-Aug-20 Appendix 4G
29-Jul-20 $ Quarterly Activity Report & Appendix 4C to 30 June 2020
01-Jul-20 $ Response to ASX Price Query
04-Jun-20 Market Update and ACW to Participate in BIO Digital
29-Apr-20 Actinogen Presentation at AAT-ADPD International Congress
23-Apr-20 $ Quarterly Activity Report & Appendix 4C
01-Apr-20 Actinogen presents latest Xanamem data at AD Conference
26-Mar-20 $ Market Update COVID-19
20-Feb-20 $ Appendix 4D & Half-Year Financial Statements
17-Feb-20 Additional R&D Tax Incentive rebate received
31-Jan-20 Appendix 3Y-Dr Bill Ketelbey
31-Jan-20 ACW – ASIC Form 484
31-Jan-20 Final share buy-back notice – Appendix 3F
28-Jan-20 $ December 2019 Quarterly Update
08-Jan-20 Actinogen at SACHS Forum and JP Morgan week
Date Price Sensitive Headline
18-Dec-19 Review of 2019 and outlook
13-Dec-19 Share Cancellation – Employee Share Plan
27-Nov-19 Managing Director share loan repayment
25-Nov-19 Results of Annual General Meeting
25-Nov-19 ACW – Managing Director’s AGM Presentation
25-Nov-19 ACW 2019 AGM Chairman’s Address
20-Nov-19 $ ACW – Response to ASX Price Query
24-Oct-19 $ R&D Tax Incentive rebate received of $4.58 million
24-Oct-19 $ September 2019 Quarterly Update
22-Oct-19 Annual Report to shareholders year ended 30 June 2019
22-Oct-19 ACW – Notice of Annual General Meeting/Proxy Form
01-Oct-19 $ Cognitive improvement demonstrated with Xanamem
30-Sep-19 Actinogen Medical Conference Call
27-Sep-19 Notification of 2019 Annual General Meeting Date
27-Sep-19 $ Trading Halt
16-Aug-19 Appendix 4G
16-Aug-19 $ Appendix 4E & Annual Report
30-Jul-19 $ June 2019 Quarterly Update
03-Jul-19 Clinical Development and Scientific Conference Update
26-Jun-19 $ Xanamem Clinical Development and Investor Update
03-Jun-19 Actinogen Medical participating in the BIO 2019 Convention
29-May-19 $ XanaHES Trial to Continue
10-May-19 Ceasing to be a substantial holder
08-May-19 Ceasing to be a substantial holder from AEF
07-May-19 $ Phase II Alzheimer’s Disease Trial – results
03-May-19 $ Trading Halt
01-May-19 Actinogen Updated Investor Presentation
24-Apr-19 $ March 2019 Quarterly Update
23-Apr-19 Change in substantial holding
15-Apr-19 Lapse of Options
12-Apr-19 Appendix 3Y-Mr Malcolm McComas
12-Apr-19 Appendix 3B
10-Apr-19 $ New Clinical Development Opportunities for Xanamem
04-Apr-19 Cleansing Notice
04-Apr-19 Appendix 3B
04-Apr-19 Appendix 3X-Malcolm McComas
04-Apr-19 Actinogen Medical appoints new Non-Executive Director
26-Mar-19 $ DSMB again reaffirms XanADu trial to continue without change
22-Mar-19 Change in substantial holding (Replacement Form 604)
22-Mar-19 Change in substantial holding
21-Mar-19 Actinogen Updated Investor Presentation
19-Mar-19 Appendix 3B
14-Mar-19 Becoming a substantial holder
04-Mar-19 Amended-Notification of Expiry of Listed Options
27-Feb-19 Notification of Expiry of Listed Options
22-Feb-19 $ ACW-Appendix 4D & Half-Year Financial Statements 31 Dec 2018
11-Feb-19 $ First participant dosed in important new Xanamem study: XanaHES
04-Feb-19 Appendix 3B
29-Jan-19 $ December 2018 Quarterly Update
07-Jan-19 ACW Presents at SACHS Neuroscience Forum during JPM Week
Date Price Sensitive Headline
13-Dec-18 Appendix 3Y-Dr George Morstyn
13-Dec-18 Appendix 3Y-Dr Bill Ketelbey
13-Dec-18 Appendix 3Y-Dr Geoff Brooke
13-Dec-18 Appendix 3B
30-Nov-18 Cleansing Notice
30-Nov-18 Appendix 3B-Exercise of Options
28-Nov-18 Appendix 3Z-Dr Jason Loveridge
28-Nov-18 Retirement of Dr Jason Loveridge as a Non-Executive Director
28-Nov-18 Results of Annual General Meeting (AGM)
28-Nov-18 Managing Director’s AGM Presentation
28-Nov-18 Chairman’s AGM Address
26-Nov-18 $ Final patient enrolled in landmark Alzheimer’s trial-XanADu
26-Nov-18 Actinogen updated investor presentation
14-Nov-18 Cleansing Notice
14-Nov-18 Appendix 3B-Exercise of Options
08-Nov-18 Supportive research highlights cortisol hypothesis
31-Oct-18 $ September 2018 Quarterly Update
31-Oct-18 Vesting Conditions Met
30-Oct-18 Actinogen to be showcased at AusBiotech Invest 2018
29-Oct-18 Enrolment target achieved for major Alzheimer’s trial-XanADu
24-Oct-18 XanADu trial to be presented at global Alzheimer conference
23-Oct-18 Annual Report to Shareholders year ended 30 June 2018
23-Oct-18 Notice of Annual General Meeting/Proxy Form
22-Oct-18 $ Recruitment to close for important Alzheimer’s trial-XanADu
17-Oct-18 Actinogen to be showcased at key conferences
16-Oct-18 Becoming a substantial holder from AEF
10-Oct-18 $ R&D Tax Rebate Received Totalling $3.15 Million
28-Sep-18 Notification of 2018 Annual General Meeting Date
18-Sep-18 Cleansing Notice
18-Sep-18 Appendix 3B-Exercise of Options
11-Sep-18 Actinogen to Present to Investors in Singapore & Sydney
29-Aug-18 Appendix 4G
29-Aug-18 Appendix 4E & Financial Statements
22-Aug-18 $ DSMB reaffirms recommendation to continue XanADu without change
15-Aug-18 $ XanADu Patient Enrolment Advancing Towards Completion
30-Jul-18 $ Updated Xanamem Clinical Development Program
25-Jul-18 $ ACW June 2018 Quarterly Report
24-Jul-18 Cleansing Notice
24-Jul-18 Appendix 3B
24-Jul-18 Ceasing to be a substantial holder
17-Jul-18 $ Placement under Share Purchase Plan Shortfall
16-Jul-18 Appendix 3Y-Dr Bill Ketelbey
16-Jul-18 Appendix 3Y-Dr Geoff Brooke
13-Jul-18 Appendix 3B-Share Purchase Plan
12-Jul-18 Share Purchase Plan Completed
12-Jul-18 Cleansing Notice
12-Jul-18 Appendix 3B
06-Jul-18 $ New Study Sites Added to Accelerate Patient Recruitment
05-Jul-18 Cleansing Notice
05-Jul-18 Appendix 3B – Exercise of Options
05-Jul-18 Results of Meeting
19-Jun-18 Change of Address
06-Jun-18 $ Share Purchase Plan
05-Jun-18 Notice of General Meeting/Proxy Form
05-Jun-18 Appendix 3Y-Dr George Morstyn
31-May-18 Becoming a substantial holder
31-May-18 Actinogen Medical to present at BIO International 2018
31-May-18 Change in substantial holding
30-May-18 Ceasing to be a substantial holder
28-May-18 Information Required Under ASX Listing Rule 3.10.5A
28-May-18 Cleansing Notice
28-May-18 Appendix 3B
28-May-18 Actinogen Medical Investor Conference Call
23-May-18 $ Placement to Raise $15m with Cornerstone Investment by Leading USA Biotech Investor
23-May-18 $ XanADu Interim Analysis-Continuation Without Change
21-May-18 $ Trading Halt
14-May-18 Cleansing Notice
14-May-18 Appendix 3B-Exercise of Options
10-May-18 XanADu Interim Analysis on track for May/June
26-Apr-18 $ March 2018 Quarterly Report
18-Apr-18 Cleansing Notice
18-Apr-18 Appendix 3B-Exercise of Options
11-Apr-18 New Analyst Report on Actinogen Medical
03-Apr-18 Appendix 3B
21-Mar-18 $ Mid-Way Point Reached in Landmark Alzheimer’s Trial – XanADu
19-Mar-18 Investor Presentation
07-Mar-18 Invitation to Investor Briefing
15-Feb-18 $ Appendix 4D & Half-Year Financial Statements
12-Feb-18 $ Strong Recruitment Progress in Alzheimer’s Trial
06-Feb-18 $ New Data Supports Cortisol Hypothesis
31-Jan-18 $ ACW – December 2017 Quarterly Report
29-Jan-18 ACW – Change in substantial holding
22-Jan-18 Appendix 3Y-Dr Geoff Brooke
22-Jan-18 Cleansing Notice
22-Jan-18 Appendix 3B
18-Jan-18 Results of Meeting
02-Jan-18 Lapse of Unlisted Options
Date Price Sensitive Headline
21-Dec-17 Change of Directors Interest Notice x 3
21-Dec-17 Appendix 3B
18-Dec-17 Notice of General Meeting/Proxy Form
14-Dec-17 Completion of Cancellation of Unvested Loan Shares
13-Dec-17 Change in substantial holding
08-Dec-17 Cleansing Notice
08-Dec-17 Appendix 3B-Placement
07-Dec-17 Letter to Ineligible Shareholders
01-Dec-17 Letter to Optionholders
01-Dec-17 Appendix 3B
01-Dec-17 $ Prospectus
01-Dec-17 Appendix 3X – Dr Morstyn
01-Dec-17 Appendix 3B
01-Dec-17 Amgen Pioneer Dr George Morstyn Joins Actinogen Board
29-Nov-17 Results of Annual General & Special General Meetings
29-Nov-17 $ Early Efficacy & Safety Data Planned for XanADu Trial
29-Nov-17 $ Placement Fully Funds Completion of XanADu Alzheimer’s Trial
29-Nov-17 Managing Director’s Annual General Meeting Presentation
29-Nov-17 Chairman’s Annual General Meeting Address
27-Nov-17 Trading Halt Request
22-Nov-17 Leading Alzheimer’s Researchers to Address Shareholders
15-Nov-17 $ R&D Rebate Received Totalling $1.22 Million
02-Nov-17 Amgen Pioneer to Join Actinogen Board
30-Oct-17 $ Quarterly Update & Appendix 4C
23-Oct-17 Annual Report to Shareholders
23-Oct-17 Notice of Special General Meeting & Proxy Form
23-Oct-17 Notice of Annual General Meeting/Proxy Form
17-Oct-17 Actinogen to be showcased at key conferences
12-Oct-17 Investor Newsletter
11-Oct-17 $ Final Major Market Patent Granted for Xanamem
22-Sep-17 Lapse of Unlisted Options
07-Sep-17 $ First patient completes landmark Alzheimer’s disease trial
18-Aug-17 $ Appendix 4E & Financial Statements
18-Aug-17 Appendix 4G
16-Aug-17 $ First UK patient treated in ground-breaking Alzheimer’s clinical trial
14-Aug-17 Final Director’s Interest Notice
14-Aug-17 Resignation of Director
26-Jul-17 $ June Quarterly Update
19-Jul-17 Actinogen Presenting at Bioshares Biotech 2017 Summit
12-Jul-17 Appendix 3B – Issue of Employee Options
07-Jul-17 Appendix 3Y – Change of Director’s Interest Notice
03-Jul-17 Lapse of Unlisted Options
22-Jun-17 $ First US patients treated in landmark Alzheimer’s disease trial
19-Jun-17 Actinogen Medical attending BIO 2017
01-Jun-17 $ First UK site goes live in global Alzheimer’s disease Clinical Trial
16-May-17 $ First patient treated in landmark Alzheimer’s disease clinical trial
09-May-17 Appendix 3B – Exercise of Options
09-May-17 Section 708A Notice
26-Apr-17 Becoming a substantial holder
26-Apr-17 Section 708A Notice
26-Apr-17 Appendix 3B – Exercise of Options
26-Apr-17 $ March Quarterly Update
29-Mar-17 Appendix 3Y – Change of Director’s Interest Notice
27-Mar-17 Latest Investor Presentation
27-Mar-17 Appendix 3Y – Change of Director’s Interest Notice
27-Mar-17 Appendix 3B
16-Mar-17 Quarterly Investor Newsletter
08-Mar-17 $ TGA Regulatory Approval for Alzheimer’s Phase II Trial
01-Mar-17 Appendix 3X – Initial Director’s Interest Notice
01-Mar-17 Actinogen Medical Appoints Dr Geoff Brooke as Chairman
27-Feb-17 $ Actinogen Medical Financial Results
10-Feb-17 $ UK Regulatory Approval for Alzheimer’s Disease Clinical Trial – XanADu
09-Feb-17 $ Xanamem research published in prestigious medical journal
06-Feb-17 Issue of Employee & Advisor Options
23-Jan-17 $ Appendix 4C – Quarterly
09-Jan-17 Ceasing to be a substantial holder
03-Jan-17 Lapse of Unlisted Options
03-Jan-17 $ FDA Approval to Commence Alzheimer’s Disease Clinical Trial
Date Price Sensitive Headline
19-Dec-16 $ Significant Advance in Development of Alzheimer’s Drug
06-Dec-16 Xanamem Research Presented at CTAD
30-Nov-16 Results of Annual General Meeting
30-Nov-16 Retirement of Martin Rogers as Chairman of Actinogen Medical
30-Nov-16 Appendix 3Z
30-Nov-16 Chairman’s AGM Address
30-Nov-16 CEO’s Presentation to AGM
26-Oct-16 $ Appendix 4C – Quarterly
24-Oct-16 Annual Report to Shareholders
24-Oct-16 Notice of Annual General Meeting / Proxy Form
14-Oct-16 Ceasing to be a Substantial Holder
06-Oct-16 Ceasing to be a Substantial Holder
05-Oct-16 Changes to the Actinogen Medical Board
29-Sep-16 $ FDA Feedback on Xanamem Alzheimer’s Trial
05-Sep-16 $ R&D Tax Rebate
01-Sep-16 Investor Update – August 2016
31-Aug-16 Appendix 4G
31-Aug-16 $ Appendix 4E & Financial Statements
24-Aug-16 Ceasing to be a Substantial Shareholder
17-Aug-16 Less Than Marketable Parcel Sale
28-Jul-16 $ Landmark Research on Excess Cortisol & Alzheimer’s Disease
20-Jul-16 $ US Patent Granted – Further Extends Xanamem Protection
15-Jul-16 US Roadshow Investor Presentation
15-Jul-16 $ Appendix 4C Quarterly
08-Jul-16 Issue of Employee Options
29-Jun-16 Xanamem and AIBL Data Showcase Cortisol Hypothesis in Alzheimer’s Disease
08-Jun-16 $ US FDA Feedback Enhances Alzheimer’s Study
20-May-16 Change of Share Register Notification
06-May-16 Section 708A Notice
06-May-16 Appendix 3B
03-May-16 BioEquity & AusBiotech Asia Investor Presentation May 2016
15-Apr-16 $ Appendix 4C – Quarterly
22-Mar-16 $ Launch of XanADu Phase II Clinical Trial
10-Mar-16 Xanamem Cortisol Hypothesis Investor Presentation
19-Feb-16 $ Appendix 4D & Half Year Report
09-Feb-16 $ R&D Tax Rebate
27-Jan-16 $ Appendix 4C – Quarterly
04-Jan-16 Appendix 3Y – Dr Bill Ketelbey
Date Price Sensitive Headline
01-Dec-15 Investor Update – December 2015
17-Nov-15 Change of Company Name
12-Nov-15 Results of AGM
12-Nov-15 CEO’s AGM Presentation
12-Nov-15 Chairman’s AGM Address
06-Nov-15 Release of Securities from Voluntary Escrow
15-Oct-15 $ Appendix 4C – Quarterly
07-Oct-15 Understanding Alzheimer’s Symposium
07-Oct-15 Annual Report to Shareholders
07-Oct-15 Notice of Annual General Meeting and Proxy Form
30-Sep-15 Expiry of Listed Options
29-Sep-15 $ Positive Trial Results for Alzheimer’s Drug Xanamem
28-Sep-15 $ Trading Halt
31-Aug-15 Appendix 4G
31-Aug-15 Expiry of Listed Options & Waiver of Listing Rule 6.24
31-Aug-15 $ Appendix 4E & Financial Statements
17-Aug-15 Investor Update August 2015
12-Aug-15 Employee Share Plan Vesting Conditions Met
11-Aug-15 Employee Share Plan Vesting Conditions Met
11-Aug-15 $ Clinical Trial Successfully Completed with Xanamem
16-Jul-15 $ Appendix 4C – Quarterly
07-Jul-15 Investor Roadshow Presentation
26-Jun-15 Change of Address & Executive Chairman Agreement
11-Jun-15 $ Excellent Research Progress with Promising Alzheimer’s Drug
21-May-15 Employee Share Plan Vesting Conditions Met
21-May-15 ASX Spotlight Series Singapore/Hong Kong May 2015
20-May-15 Appendix 3B
20-May-15 Appendix 3Y: Dr Anton Uvarov
20-May-15 Appendix 3Y: Dr Bill Ketelbey
20-May-15 Appendix 3Y: Dr Jason Loveridge
20-May-15 Appendix 3Y: Martin Rogers
14-May-15 Notice of Change of Interests of Substantial Holder
12-May-15 $ Successful Completion of First Stage of Alzheimer’s Drug Trial
07-May-15 Change in Substantial Holding
07-May-15 Ceasing to be a Substantial Holder
06-May-15 Information Required Under Listing Rule 3.10.5A
06-May-15 Section 708A Notice
06-May-15 Appendix 3B
01-May-15 Notice Under ASIC Class Order (CO 09-425)
30-Apr-15 $ Share Purchase Plan
28-Apr-15 Change in Substantial Shareholding
27-Apr-15 Change in Substantial Shareholding x 2
24-Apr-15 $ Ethics Approval Granted for Second Stage of Phase I Study
24-Apr-15 $ Successful Capital Raising to Support Alzheimer’s Research
24-Apr-15 $ Appendix 4C: Quarterly
22-Apr-15 $ Trading Halt
16-Apr-15 $ Further Clinical Trial Update on Xanamem
16-Apr-15 Xanamem Clinical Advisory Board (XCAB) Conference Call Transcript
15-Apr-15 Investor Update – April 2015
13-Apr-15 $ EU Patent Granted – Further Extends Xanamem Protection
13-Apr-15 Investor Presentation – April 2015
13-Apr-15 Xanamem Clinical Advisory Board (XCAB) Conference Call
24-Mar-15 $ Clinical Trial Update – Xanamem Drug for Alzheimer’s Dementia
17-Mar-15 Powerhouse Alzheimer’s Advisory Board to Drive Xanamem Development
12-Mar-15 $ Response to Price Query Letter
09-Mar-15 Investor Presentation – March 2015
27-Feb-15 $ Appendix 4D & Half Year Report
24-Feb-15 $ First Participants Recruited for Second Phase I Xanamem Study
24-Feb-15 Employee Share Plan Vesting Conditions Met
17-Feb-15 Investor Presentation – February 2015
16-Feb-15 $ Ethics Approval Granted for Second Phase I Study of Xanamem
16-Feb-15 Investor Update – February 2015
29-Jan-15 $ Appendix 4C: Quarterly
16-Jan-15 Employee Share Plan Vesting Conditions Met
09-Jan-15 US Investor Presentation – January 2015
07-Jan-15 $ Response to ASX Query – Price Query

Financial Reports

View All >>

Annual General Meeting

2020 Annual General Meeting

The 2020 Annual General Meeting was held at 10.30am AEDT on Friday, 27 November 2020 as a fully virtual online event.

ANALYST COVERAGE AND REPORTS

Date Analyst Headline
12-Nov-20 Jonas Peculias
12-Nov-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
15-Oct-20 Jonas Peculias
15-Oct-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
17-Sep-20 Jonas Peculias
17-Sep-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue
13-Aug-20 Jonas Peculias
13-Aug-20 Analyst: Jonas Peculias

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue

View All >>

INVESTOR UPDATES AND MEDIA

Date Published By Headline
27-Nov-20 Open Briefing
27-Nov-20 Published by: Open Briefing
Actinogen Medical Annual General Meeting 27 Nov 2020: Webcast presentation
27-Nov-20 Actinogen Medical
27-Nov-20 Published by: Actinogen Medical
Actinogen Medical Annual General Meeting 27 Nov 2020: Audio only
20-Nov-20 Biotech Daily
20-Nov-20 Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
13-Nov-20 Biotech Daily
13-Nov-20 Published by: Biotech Daily
Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m
09-Nov-20 The Market Herald
09-Nov-20 Published by: The Market Herald
Actinogen Medical (ASX:ACW) files new patent applications

View All >>

Date Published By Headline
27-Nov-20 Open Briefing
27-Nov-20 Published by: Open Briefing
Actinogen Medical Annual General Meeting 27 Nov 2020: Webcast presentation
20-Nov-20 Biotech Daily
20-Nov-20 Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
13-Nov-20 Biotech Daily
13-Nov-20 Published by: Biotech Daily
Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m
09-Nov-20 The Market Herald
09-Nov-20 Published by: The Market Herald
Actinogen Medical (ASX:ACW) files new patent applications
09-Nov-20 Melbourne Online News
09-Nov-20 Published by: Melbourne Online News
Actinogen share price jumps 4.5% on patent news // Motley Fool Australia

View All >>

View All >>

Date Published By Headline
27-Nov-20 Open Briefing
27-Nov-20 Published by: Open Briefing
Actinogen Medical Annual General Meeting 27 Nov 2020: Webcast presentation
09-Nov-20 Finance News Network
09-Nov-20 Published by: Finance News Network
Actinogen Medical (ASX:ACW) tackling Alzheimer’s by inhibiting excess cortisol production in the brain
03-Nov-20 The Market Herald
03-Nov-20 Published by: The Market Herald
Actinogen Medical (ASX:ACW) to test Fragile X syndrome treatment in Melbourne clinical trial
WATCH FROM 4:50 to 13:33
02-Nov-20 Boardroom Media
02-Nov-20 Published by: Boardroom Media
ASX: ACW World first medical trial Fragile X Syndrome
29-Oct-20 Monsoon Communications
29-Oct-20 Published by: Monsoon Communications
Monsoon Morning Twilight Investor Briefing webinar video (28 Oct 2020) – watch from 17:50
Dr Bill Ketelbey provided a clinical development update

View All >>

Date Published By Headline
19-Nov-19 Actinogen Medical
19-Nov-19 Published by: Actinogen Medical
Investor Newsletter: Nov 2019
16-Apr-19 Actinogen Medical
16-Apr-19 Published by: Actinogen Medical
Investor Newsletter: Apr 2019
12-Dec-18 Actinogen Medical
12-Dec-18 Published by: Actinogen Medical
Investor Newsletter: Dec 2018
12-Oct-17 Actinogen Medical
12-Oct-17 Published by: Actinogen Medical
Investor Newsletter: October 2017
16-Mar-17 Actinogen Medical
16-Mar-17 Published by: Actinogen Medical
Quarterly Newsletter: Mar 2017

View All >>

Date Published By Headline
01-Dec-20 Switzer Financial Group
01-Dec-20 Published by: Switzer Financial Group
Switzer Small & Micro-Cap Virtual Investor Day (1 & 2 Dec 2020)
28-Oct-20 Monsoon Communications
28-Oct-20 Published by: Monsoon Communications
Morning Twilight Investor Briefing 11:00am to 11:40am
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call (19 Oct 2020 at 11.00am AEDT)
08-Sep-20 ASX
08-Sep-20 Published by: ASX
ASX Small & Mid-Cap Conference (8-10 Sep 2020)
28-Jul-20 Finance News Network
28-Jul-20 Published by: Finance News Network
FNN CEO Showcase: Sydney (28 Jul 2020) Virtual Event

View All >>

FREQUENTLY ASKED QUESTIONS

The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine from Edinburgh University, a company focused on the development of brain penetrant 11β-HSD1 enzyme inhibitors for the treatment of cognitive impairment.  The lead drug in development by Corticrine was Xanamem. Corticrine received A$25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 (Xanamem) in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.

Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000

The share registry is managed by Link Market Services. To login and access your holding information, please go to: https://www.linkmarketservices.com.au

The share registry is managed by Link Market Services and shareholders can check their shareholdings by logging into https://www.linkmarketservices.com.au

All company shares are traded on the ASX and can be bought or sold through a licensed stock broker. The process of buying or selling shares is explained on the ASX website, please go to https://www.asx.com.au/products/shares/buying-selling-shares.htm

Non-Australian residents wishing to invest in ACW shares should contact a licensed stock broker which offers cross border transaction services with Australia. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities. Investors should note that ACW is only listed on the Australian Securities Exchange.

All annual reports are available on our website through this link – https://actinogen.com.au/investor-centre/#financial-reports

Current share prices are available on the ASX website www.asx.com.au and can be searched using the Company’s ASX ticker symbol: ACW. Our Investor Centre also includes the delayed share graph – https://actinogen.com.au/investor-centre/#share-price

The ASX ticker code for the Company is ASX:ACW

The Company’s end of financial year is the 30th of June

As a listed company Actinogen is required to hold its annual general meeting within five months of its financial year end.  Accordingly, shareholders will be notified in the months of September or October, approximately 28 days in advance of when and where the AGM will be held. Typically, Actinogen holds its AGM towards the end of November.

The Company’s auditors are Ernst and Young

Our Corporate Governance policy can be found on our website at: https://actinogen.com.au/investor-centre/#corporate-governance This includes our Board Charter, Code of Conduct, Continuous Disclosure Policy, Directors Skills Matrix, Diversity Policy, Nomination Committee Charter, Performance Evaluation Practices, Procedures for Selection and Appointment of Directors, Remuneration Committee Charter, Risk Management and Internal Compliance and Control, the Securities Trading Policy and Shareholders Communication Policy.

The Company does not currently have a dividend policy as the Company is not yet revenue generating. The Board reviews its growth strategy at regular intervals and assesses it against the Company’s working capital requirements and growth opportunities. Until the Company is generating returns, it is not expected to implement a dividend policy.

CODES AND GUIDELINES

AusBiotech has made available reports designed to assist corporate governance in the sector.

  • The Code of Best Practice for Reporting Life Sciences Companies (the Code)
  • The Guide for Life Science Company Directors (the Guide)
  • Corporate Governance in the ASX-listed Life Sciences Sector